Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.

You may also be interested in...



Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%

Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.

Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%

Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.

Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia

Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel